Sort By: Author - Journal - Title - Year

Search: Clear

---

(none). Diagnosis and classification of diabetes mellitus. Diabetes Care. 2004;27 Suppl 1:S5-S10.

Abadji V, Lin S, Taha G, et al. (R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. Journal of medicinal chemistry. 1994;37 (12):1889-93.

Abood ME, Martin BR. Neurobiology of marijuana abuse. Trends Pharmacol Sci. 1992;13:201-6.

Abood ME, Martin BR. Molecular neurobiology of the cannabinoid receptor. Int Rev Neurobiol. 1996;39:197-221.

Abood ME, Sauss C, Fan F, Tilton CL, Martin BR. Development of behavioral tolerance to delta 9-THC without alteration of cannabinoid receptor binding or mRNA levels in whole brain. Pharmacol Biochem Behav. 1993;46:575-9.

Aceto MD, Scates SM, Lowe JA, Martin BR. Dependence on delta 9-tetrahydrocannabinol: studies on precipitated and abrupt withdrawal. J Pharmacol Exp Ther. 1996;278:1290-5.

Aceto MD, Scates SM, Lowe JA, Martin BR. Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A. Eur J Pharmacol. 1995;282:R1-2.

Aceto MD, Scates SM, Razdan RK, Martin BR. Anandamide, an endogenous cannabinoid, has a very low physical dependence potential. J Pharmacol Exp Ther. 1998;287:598-605.

Adam AS, Wenger T, Csillag A. The cannabinoid CB(1) receptor antagonist rimonabant dose-dependently inhibits memory recall in the passive avoidance task in domestic chicks (Gallus domesticus). Brain research bulletin. 2008;76 (3):272-4.

Adami M, Frati P, Bertini S, et al. Gastric antisecretory role and immunohistochemical localization of cannabinoid receptors in the rat stomach. British Journal of Pharmacology. 2002;135 (7):1598-606.

Adams IB, Compton DR, Martin BR. Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain. J Pharmacol Exp Ther. 1998;284:1209-17.

Adams IB, Martin BR. Cannabis: pharmacology and toxicology in animals and humans. Addiction. 1996;91:1585-614.

Adams IB, Ryan W, Singer M, Razdan RK, Compton DR, Martin BR. Pharmacological and behavioral evaluation of alkylated anandamide analogs. Life Sci. 1995;56:2041-8.

Adams IB, Ryan W, Singer M, Thomas BF, Compton DR, Razdan RK, Martin BR. Evaluation of cannabinoid receptor binding and in vivo activities for anandamide analogs. J Pharmacol Exp Ther. 1995;273:1172-81.

Adams MD, Earnhardt JT, Martin BR, Harris LS, Dewey WL, Razdan RK. A cannabinoid with cardiovascular activity but no overt behavioral effects. Experientia. 1977;33:1204-5.

Addy C, Li S, Agrawal N, et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of Taranabant, a Novel Selective Cannabinoid-1 Receptor Inverse Agonist, for the Treatment of Obesity: Results From a Double-Blind, Placebo-Controlled, Single Oral Dose Study in Healthy Volunteers. J Clin Pharmacol. 2008;.

Addy C, Rothenberg P, Li S, et al. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers. J Clin Pharmacol. 2008;48 (6):734-44.

Addy C, Wright H, Van LK, et al. The Acyclic CB1R Inverse Agonist Taranabant Mediates Weight Loss by Increasing Energy Expenditure and Decreasing Caloric Intake. Cell metabolism. 2008;7 (1):68-78.

Addy C, Wright H, Van LK, et al. The Acyclic CB1R Inverse Agonist Taranabant Mediates Weight Loss by Increasing Energy Expenditure and Decreasing Caloric Intake: Supplemental Results and Discussion. Cell metabolism. 2008;7:68-78.

Agarwal A, Pacher P, Tegeder I, et al. Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nature Neuroscience. 2007;10 (7):870-9.

Ahn H, Johnson DS, Fitzgerald LR, et al. Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity. Biochemistry. 2007;46 (45):13019-30.

Ahn H, Johnson DS, Fitzgerald LR, et al. Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity. Biochemistry. 2007;46 (45):13019-30.

Aja, S.Moran, T. H.. Recent advances in obesity: adiposity signaling and fat metabolism in energy homeostasis. Adv Psychosom Med. 2006;27:1-23.

Akinshola BE, Chakrabarti A, Onaivi ES. In-vitro and in-vivo action of cannabinoids. Neurochemical research. 1999;24 (10):1233-40.

Alberts, BJohnson, ALewis, JRaff, MRoberts, KWalter, P. Molecular Biology of the Cell, 4th ed. No Journal Name. 2002;.

Aliotta SL, Vlasnik JJ, Delor B. Enhancing adherence to long-term medical therapy: a new approach to assessing and treating patients. Advances in therapy. 2004;21 (4):214-31.

Alonso R, Voutsinos B, Fournier M, et al. Blockade of cannabinoid receptors by SR141716 selectively increases Fos expression in rat mesocorticolimbic areas via reduced dopamine D2 function. Neuroscience. 1999;91 (2):607-20.

Alozie SO, Martin BR, Harris LS, Dewey WL. 3H-delta 9-Tetrahydrocannabinol, 3H-cannabinol and 3H-cannabidiol: penetration and regional distribution in rat brain. Pharmacol Biochem Behav. 1980;12:217-21.

Ameri A. The effects of cannabinoids on the brain. Progress in neurobiology. 1999;58 (4):315-48.

Ameri, A.. The effects of cannabinoids on the brain. Prog Neurobiol. 1999;58:315-48.

Andersson U, Filipsson K, Abbott CR, et al. AMP-activated protein kinase plays a role in the control of food intake. J Biol Chem. 2004;279 (13):12005-8.

Anggadiredja K, Nakamichi M, Hiranita T, et al. Endocannabinoid system modulates relapse to methamphetamine seeking: possible mediation by the arachidonic acid cascade. Neuropsychopharmacology. 2004;29 (8):1470-8.

Appendino G, Ech-Chahad A, Minassi A, Bacchiega S, De PL, Di Marzo V. Structure-activity relationships of the ultrapotent vanilloid resiniferatoxin (RTX): the homovanillyl moiety. Bioorganic & medicinal chemistry letters. 2007;17 (1):132-5.

Arenos JD, Musty RE, Bucci DJ. Blockade of cannabinoid CB1 receptors alters contextual learning and memory. Eur J Pharmacol. 2006;539 (3):177-83.

Arenos, J. D.Musty, R. E.Bucci, D. J.. Blockade of cannabinoid CB1 receptors alters contextual learning and memory. Eur J Pharmacol. 2006;539:177-83.

Arevalo C, de MR, Hernandez-Tristan R. Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters. Pharmacology, biochemistry, and behavior. 2001;70 (1):123-31.

Arevalo-Martin A, Garcia-Ovejero D, Gomez O, et al. CB(2) cannabinoid receptors as an emerging target for demyelinating diseases: from neuroimmune interactions to cell replacement strategies. British Journal of Pharmacology. 2008;153 (2):216-25.

Arevalo-Martin A, Vela JM, Molina-Holgado E, Borrell J, Guaza C. Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J Neurosci. 2003;23 (7):2511-6.

Arnold JC. The role of endocannabinoid transmission in cocaine addiction. Pharmacology, biochemistry, and behavior. 2005;81 (2):396-406.

Arnone M, Maruani J, Chaperon F, et al. Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology. 1997;132 (1):104-6.

Aronne LJ. Is rimonabant a safe and effective treatment for obesity?. Nature clinical practice. 2007;3 (5):388-9.

Aronne LJ, Thornton-Jones ZD. New targets for obesity pharmacotherapy. Clin Pharmacol Ther. 2007;81 (5):748-52.

Ashton CH, Moore PB, Gallagher PJ, Young AH. Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential. Journal of psychopharmacology (Oxford, England). 2005;19 (3):293-300.

Ashton JC, Rahman RM, Nair SM, Sutherland BA, Glass M, Appleton I. Cerebral hypoxia-ischemia and middle cerebral artery occlusion induce expression of the cannabinoid CB2 receptor in the brain. Neuroscience letters. 2007;412 (2):114-7.

Aung MM, Griffin G, Huffman JW, Wu M, Keel C, Yang B, Showalter VM, Abood ME, Martin BR. Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB(1) and CB(2) receptor binding. Drug Alcohol Depend. 2000;60:133-40.

Avramoglu RK, Basciano H, Adeli K. Lipid and lipoprotein dysregulation in insulin resistant states. Clin Chim Acta. 2006;368 (1-2):1-19.

Awumey EM, Howlett AC, Diz DI. Is there a role for anandamide in cardiovascular regulation? Insights from studies of endocannabinoid metabolism. Am J Physiol Heart Circ Physiol. 2005;289 (2):H520-1.

Ayyad C, Andersen T. Long-term efficacy of dietary treatment of obesity: a systematic review of studies published between 1931 and 1999. Obesity Reviews. 2000;1 (2):113-9.

Bab I, Ofek O, Tam J, Rehnelt J, Zimmer A. Endocannabinoids and the regulation of bone metabolism. Journal of neuroendocrinology. 2008;20 Suppl 1:69-74.

Bab I, Zimmer A. Cannabinoid receptors and the regulation of bone mass. British Journal of Pharmacology. 2008;153 (2):182-8.

Bacci A, Huguenard JR, Prince DA. Long-lasting self-inhibition of neocortical interneurons mediated by endocannabinoids. Nature. 2004;431 (7006):312-6.

Badman MK, Flier JS. The gut and energy balance: visceral allies in the obesity wars. Science. 2005;307 (5717):1909-14.

Badman, M. K.Flier, J. S.. The gut and energy balance: visceral allies in the obesity wars. Science. 2005;307:1909-14.

Bahr BA, Karanian DA, Makanji SS, Makriyannis A. Targeting the endocannabinoid system in treating brain disorders. Expert Opinion on Investigational Drugs . 2006;15 (4):351-65.

Baker D, Pryce G, Croxford JL, et al. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature. 2000;404 (6773):84-7.

Baker D, Pryce G, Davies WL, Hiley CR. In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol Sci. 2006;27 (1):1-4.

Baker MB, Pryce G, Croxford JL, et al. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J. 2001;15 (2):300-2.

Baker, D.Pryce, G.Davies, W. L.Hiley, C. R.. In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol Sci. 2006;27:1-4.

Balasubramanyam, A. Endocannabinoids: novel regulators of energy balance. No Journal Name. ;.

Ballantyne, CO’Keefe, JGotto, A. Dyslipidemia Essentials. No Journal Name. 2005;.

Banasch M, Goetze O, Schmidt WE, Meier JJ. Rimonabant as a novel therapeutic option for nonalcoholic steatohepatitis. Liver International. 2007;27 (8):1152-5.

Barann M, Molderings G, Bruss M, Bonisch H, Urban BW, Gothert M. Direct inhibition by cannabinoids of human 5-HT3A receptors: probable involvement of an allosteric modulatory site. British Journal of Pharmacology. 2002;137 (5):589-96.

Barann, M.Molderings, G.Bruss, M.Bonisch, H.Urban, B. W.Gothert, M.. Direct inhibition by cannabinoids of human 5-HT3A receptors: probable involvement of an allosteric modulatory site. Br J Pharmacol. 2002;137:589-96.

Bardo MT. Neuropharmacological mechanisms of drug reward: beyond dopamine in the nucleus accumbens. Critical reviews in neurobiology. 1998;12 (1-2):37-67.

Bari M, Battista N, Fezza F, Gasperi V, Maccarrone M. New insights into endocannabinoid degradation and its therapeutic potential. Mini reviews in medicinal chemistry. 2006;6 (3):257-68.

Bari M, Spagnuolo P, Fezza F, et al. Effect of lipid rafts on Cb2 receptor signaling and 2-arachidonoyl-glycerol metabolism in human immune cells. Journal of Immunology. 2006;177 (8):4971-80.

Bar-Joseph A, Berkovitch Y, Adamchik J, Biegon A. Neuroprotective activity of HU-211, a novel NMDA antagonist, in global ischemia in gerbils. Molecular and chemical neuropathology / sponsored by the International Society for Neurochemistry and the World Federation of Neurology and research groups on neurochemistry and cerebrospinal fluid. 1994;23 (2-3):125-35.

Barna I, Zelena D, Arszovszki AC, Ledent C. The role of endogenous cannabinoids in the hypothalamo-pituitary-adrenal axis regulation: in vivo and in vitro studies in CB1 receptor knockout mice. Life Sci. 2004;75 (24):2959-70.

Barnett-Norris J, Lynch D, Reggio PH. Lipids, lipid rafts and caveolae: their importance for GPCR signaling and their centrality to the endocannabinoid system. Life Sci. 2005;77 (14):1625-39.

Barrett RL, Wiley JL, Balster RL, Martin BR. Pharmacological specificity of delta 9-tetrahydrocannabinol discrimination in rats. Psychopharmacology (Berl). 1995;118:419-24.

Basavarajappa BS. The endocannabinoid signaling system: a potential target for next-generation therapeutics for alcoholism. Mini reviews in medicinal chemistry. 2007;7 (8):769-79.

Basavarajappa BS. Critical enzymes involved in endocannabinoid metabolism. Protein and peptide letters. 2007;14 (3):237-46.

Basavarajappa BS, Hungund BL. Chronic ethanol increases the cannabinoid receptor agonist anandamide and its precursor N-arachidonoylphosphatidylethanolamine in SK-N-SH cells. J Neurochem. 1999;72 (2):522-8.

Basavarajappa BS, Hungund BL. Role of the endocannabinoid system in the development of tolerance to alcohol. Alcohol and alcoholism (Oxford, Oxfordshire). 2005;40 (1):15-24.

Basavarajappa BS, Saito M, Cooper TB, Hungund BL. Chronic ethanol inhibits the anandamide transport and increases extracellular anandamide levels in cerebellar granule neurons. Eur J Pharmacol. 2003;466 (1-2):73-83.

Basavarajappa BS, Saito M, Cooper TB, Hungund BL. Stimulation of cannabinoid receptor agonist 2-arachidonylglycerol by chronic ethanol and its modulation by specific neuromodulators in cerebellar granule neurons. . 2000;1535 (1):78-86.

Basavarajappa BS, Yalamanchili R, Cravatt BF, Cooper TB, Hungund BL. Increased ethanol consumption and preference and decreased ethanol sensitivity in female FAAH knockout mice. Neuropharmacology. 2006;50 (7):834-44.

Baskfield CY, Martin BR, Wiley JL. Differential effects of delta9-tetrahydrocannabinol and methanandamide in CB1 knockout and wild-type mice. J Pharmacol Exp Ther. 2004;309:86-91.

Bass CE, Griffin G, Grier M, Mahadevan A, Razdan RK, Martin BR. SR-141716A-induced stimulation of locomotor activity. A structure-activity relationship study. Pharmacol Biochem Behav. 2002;74:31-40.

Bass CE, Martin BR. Time course for the induction and maintenance of tolerance to Delta(9)-tetrahydrocannabinol in mice. Drug Alcohol Depend. 2000;60:113-9.

Bass CE, Welch SP, Martin BR. Reversal of delta 9-tetrahydrocannabinol-induced tolerance by specific kinase inhibitors. Eur J Pharmacol. 2004;496:99-108.

Bates ER, Lau WC. Controversies in antiplatelet therapy for patients with cardiovascular disease. Circulation. 2005;111 (17):e267-71.

Batkai S, Pacher P, Jarai Z, Wagner JA, Kunos G. Cannabinoid antagonist SR-141716 inhibits endotoxic hypotension by a cardiac mechanism not involving CB1 or CB2 receptors. Am J Physiol Heart Circ Physiol. 2004;287 (2):H595-600.

Batkai S, Pacher P, Osei-Hyiaman D, et al. Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation. 2004;110 (14):1996-2002.

Batkai, S.Pacher, P.Osei-Hyiaman, D.Radaeva, S.Liu, J.Harvey-White, J.Offertaler, L.Mackie, K.Rudd, M. A.Bukoski, R. D.Kunos, G.. Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation. 2004;110:1996-2002.

Battista N, Fezza F, Finazzi-Agro A, Maccarrone M. The endocannabinoid system in neurodegeneration. The Italian journal of biochemistry. 2006;55 (3-4):283-9.

Battista N, Pasquariello N, di TE, Maccarrone M. Interplay between endocannabinoids, steroids and cytokines in the control of human reproduction. Journal of neuroendocrinology. 2008;20 Suppl 1:82-9.

Beardsley PM, Martin BR. Effects of the cannabinoid CB(1) receptor antagonist, SR141716A, after Delta(9)-tetrahydrocannabinol withdrawal. Eur J Pharmacol. 2000;387:47-53.

Beardsley PM, Scimeca JA, Martin BR. Studies on the agonistic activity of delta 9-11-tetrahydrocannabinol in mice, dogs and rhesus monkeys and its interactions with delta 9-tetrahydrocannabinol. J Pharmacol Exp Ther. 1987;241:521-6.

Beatrice, M.Gabriella, M.Francesca, G.Oliana, C.. Endocannabinoid system in Xenopus laevis development: CB1 receptor dynamics. FEBS Lett. 2006;580:1941-5.

Beaulieu P, Ware M. Reassessment of the role of cannabinoids in the management of pain. Current Opinion in Anaesthesiology. 2007;20 (5):473-7.

Belayev L, Bar-Joseph A, Adamchik J, Biegon A. HU-211, a nonpsychotropic cannabinoid, improves neurological signs and reduces brain damage after severe forebrain ischemia in rats. Molecular and chemical neuropathology / sponsored by the International Society for Neurochemistry and the World Federation of Neurology and research groups on neurochemistry and cerebrospinal fluid. 1995;25 (1):19-33.

Belayev L, Busto R, Zhao W, Ginsberg MD. HU-211, a novel noncompetitive N-methyl-D-aspartate antagonist, improves neurological deficit and reduces infarct volume after reversible focal cerebral ischemia in the rat. Stroke. 1995;26 (12):2313-9; discussion 2319-20.

Bellocchio L, Cervino C, Vicennati V, Pasquali R, Pagotto U. Cannabinoid type 1 receptor: another arrow in the adipocytes' bow. Journal of neuroendocrinology. 2008;20 Suppl 1:130-8.

Beltramo M, Bernardini N, Bertorelli R, et al. CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. European Journal of Neuroscience. 2006;23 (6):1530-8.

Beltramo M, de FF, Navarro M, et al. Reversal of dopamine D(2) receptor responses by an anandamide transport inhibitor. J Neurosci. 2000;20 (9):3401-7.

Benedetti F, Arduino C, Costa S, et al. Loss of expectation-related mechanisms in Alzheimer's disease makes analgesic therapies less effective. Pain. 2006;121 (1-2):133-44.

Benito C, Nunez E, Tolon RM, et al. Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J Neurosci. 2003;23 (35):11136-41.

Benito C, Romero JP, Tolon RM, et al. Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. J Neurosci. 2007;27 (9):2396-402.

Benito C, Tolon RM, Pazos MR, Nunez E, Castillo AI, Romero J. Cannabinoid CB(2) receptors in human brain inflammation. British Journal of Pharmacology. 2008;153 (2):277-85.

Benoit SC, Tracy AL. Behavioral controls of food intake. Peptides. 2008;29 (1):139-47.

Bensaid M, Gary-Bobo M, Esclangon A, et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol. 2003;63 (4):908-14.

Bensaid, M.Gary-Bobo, M.Esclangon, A.Maffrand, J. P.Le Fur, G.Oury-Donat, F.Soubrie, P.. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol. 2003;63:908-14.

Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nature Med. 2001;7 (8):947-53.

Berg, A. H.Combs, T. P.Du, X.Brownlee, M.Scherer, P. E.. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med. 2001;7:947-53.

Berger A, Crozier G, Bisogno T, Cavaliere P, Innis S, Di Marzo V. Anandamide and diet: inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-acylethanolamines in piglets. Proc Natl. Acad. Sci. USA. 2001;98 (11):6402-6.

Berger C, Schmid PC, Schabitz WR, Wolf M, Schwab S, Schmid HH. Massive accumulation of N-acylethanolamines after stroke. Cell signalling in acute cerebral ischemia?. J Neurochem. 2004;88 (5):1159-67.

Berger JJ, Barnard RJ. Effect of diet on fat cell size and hormone-sensitive lipase activity. J Appla Physiol. 1999;87 (1):227-32.

Berger, J. J.Barnard, R. J.. Effect of diet on fat cell size and hormone-sensitive lipase activity. J Appl Physiol. 1999;87:227-32.

Berghuis P, Rajnicek AM, Morozov YM, et al. Hardwiring the brain: endocannabinoids shape neuronal connectivity. Science. 2007;316 (5828):1212-6.

Bergman RN. Pathogenesis and prediction of diabetes mellitus: lessons from integrative physiology. The Mount Sinai journal of medicine, New York. 2002;69 (5):280-90.

Bergman RN, Ader M, Huecking K, Van CG. Accurate assessment of beta-cell function: the hyperbolic correction. Diabetes. 2002;51 Suppl 1:S212-20.

Bergman, R. N.. Pathogenesis and prediction of diabetes mellitus: lessons from integrative physiology. Mt Sinai J Med. 2002;69:280-90.

Bermudez-Silva FJ, Sanchez-Vera I, Suarez J, et al. Role of cannabinoid CB2 receptors in glucose homeostasis in rats. Eur J Pharmacol. 2007;565 (1-3):207-11.

Bermudez-Silva FJ, Suarez J, Baixeras E, et al. Presence of functional cannabinoid receptors in human endocrine pancreas. Diabetologia. 2007;81 (1):336-43.

Bermudez-Siva FJ, Serrano A, Diaz-Molina FJ, et al. Activation of cannabinoid CB1 receptors induces glucose intolerance in rats. Eur J Pharmacol. 2006;531 (1-3):282-4.

Bermudez-Siva, F. J.Serrano, A.Diaz-Molina, F. J.Sanchez Vera, I.Juan-Pico, P.Nadal, A.Fuentes, E.Rodriguez de Fonseca, F.. Activation of cannabinoid CB1 receptors induces glucose intolerance in rats. Eur J Pharmacol. 2006;531:282-4.

Bernstein LE, Berry J, Kim S, Canavan B, Grinspoon SK. Effects of etanercept in patients with the metabolic syndrome. Arch Intern Med. 2006;166 (8):902-8.

Bersot T, Kellick KA, Morris CM, Haffner SM, Harris WS. Hypertriglyceridemia: management of atherogenic dyslipidemia. J Fam Pract. 2006;55 (7):S1-8.

Berthoud HR, Morrison C. The brain, appetite, and obesity. Annual review of psychology. 2008;59:55-92.

Bifulco M, Grimaldi C, Gazzerro P, Pisanti S, Santoro A. Rimonabant: just an antiobesity drug? Current evidence on its pleiotropic effects. Mol Pharmacol. 2007;71 (6):1445-56.

Bifulco M, Laezza C, Valenti M, Ligresti A, Portella G, D IM. A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. FASEB J. 2004;18 (13):1606-8.

Bifulco M, Malfitano AM, Pisanti S, Laezza C. Endocannabinoids in endocrine and related tumours. Endocrine-related cancer. 2008;15 (2):391-408.

Bifulco M, Malfitano AM, Pisanti S, Laezza C. Endocannabinoids in endocrine and related tumours. Endocrine-related cancer. 2008;15 (2):391-408.

Bilsland LG, Dick JR, Pryce G, et al. Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice. FASEB J. 2006;20 (7):1003-5.

Bisogno T, Cascio MG, Saha B, et al. Development of the first potent and specific inhibitors of endocannabinoid biosynthesis. . 2006;1761 (2):205-12.

Bisogno T, Ligresti A, Di Marzo V. The endocannabinoid signalling system: biochemical aspects. Pharmacology, biochemistry, and behavior. 2005;81 (2):224-38.

Bisogno, T.Ligresti, A.Di Marzo, V.. The endocannabinoid signalling system: biochemical aspects. Pharmacol Biochem Behav. 2005;81:224-38.

Blair RE, Deshpande LS, Sombati S, Falenski KW, Martin BR, DeLorenzo RJ. Activation of the cannabinoid type-1 receptor mediates the anticonvulsant properties of cannabinoids in the hippocampal neuronal culture models of acquired epilepsy and status epilepticus. J Pharmacol Exp Ther. 2006;317:1072-8.

Blankman JL, Simon GM, Cravatt BF. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chemistry & biology. 2007;14 (12):1347-56.

Blazquez C, Carracedo A, Barrado L, et al. Cannabinoid receptors as novel targets for the treatment of melanoma. FASEB J. 2006;20 (14):2633-5.

Blazquez C, Salazar M, Carracedo A, et al. Cannabinoids inhibit glioma cell invasion by down-regulating matrix metalloproteinase-2 expression. Cancer research. 2008;68 (6):1945-52.

Blednov YA, Cravatt BF, Boehm SL, Walker D, Harrison RA. Role of endocannabinoids in alcohol consumption and intoxication: studies of mice lacking fatty acid amide hydrolase. Neuropsychopharmacology. 2007;32 (7):1570-82.

Bluher M, Engeli S, Kloting N, et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes. 2006;55 (11):3053-60.

Bodnar, R. J.Klein, G. E.. Endogenous opiates and behavior: 2004. Peptides. 2005;26:2629-711.

Bohme GA, Laville M, Ledent C, Parmentier M, Imperato A. Enhanced long-term potentiation in mice lacking cannabinoid CB1 receptors. Neuroscience. 2000;95 (1):5-7.

Bortolato M, Campolongo P, Mangieri RA, et al. Anxiolytic-like properties of the anandamide transport inhibitor AM404. Neuropsychopharmacology. 2006;31 (12):2652-9.

Bortolato M, Mangieri RA, Fu J, et al. Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biological psychiatry. 2007;62 (10):1103-10.

Bouaboula M, Hilairet S, Marchand J, Fajas L, Le FG, Casellas P. Anandamide induced PPARgamma transcriptional activation and 3T3-L1 preadipocyte differentiation. Eur J Pharmacol. 2005;517 (3):174-81.

Bouaboula M, Perrachon S, Milligan L, et al. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J Biol Chem. 1997;272 (35):22330-9.

Bourne C, Roy S, Wiley JL, Martin BR, Thomas BF, Mahadevan A, Razdan RK. Novel, potent THC/anandamide (hybrid) analogs. Bioorg Med Chem. 2007;15:7850-64.

Boyd ST, Fremming BA. Rimonabant--a selective CB1 antagonist. Ann Pharmacother. 2005;39 (4):684-90.

Boydell J, Dean K, Dutta R, Giouroukou E, Fearon P, Murray R. A comparison of symptoms and family history in schizophrenia with and without prior cannabis use: implications for the concept of cannabis psychosis. Schizophrenia research. 2007;93 (1-3):203-10.

Bracey MH, Hanson MA, Masuda KR, Stevens RC, Cravatt BF. Structural adaptations in a membrane enzyme that terminates endocannabinoid signaling. Science. 2002;298 (5599):1793-6.

Braida D, Limonta V, Malabarba L, Zani A, Sala M. 5-HT1A receptors are involved in the anxiolytic effect of Delta9-tetrahydrocannabinol and AM 404, the anandamide transport inhibitor, in Sprague-Dawley rats. Eur J Pharmacol. 2007;555 (2-3):156-63.

Breivogel CS, Childers SR. The functional neuroanatomy of brain cannabinoid receptors. Neurobiology of Disease. 1998;5 (6 Pt B):417-31.

Breivogel CS, Griffin G, Di Marzo V, Martin BR. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol. 2001;60:155-63.

Breivogel CS, Griffin G, Di Marzo V, Martin BR. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol. 2001;60 (1):155-63.

Breivogel CS, Scates SM, Beletskaya IO, Lowery OB, Aceto MD, Martin BR. The effects of delta9-tetrahydrocannabinol physical dependence on brain cannabinoid receptors. Eur J Pharmacol. 2003;459:139-50.

Breivogel CS, Sim LJ, Childers SR. Regional differences in cannabinoid receptor/G-protein coupling in rat brain. The Journal of Pharmacology and Experimental Therapeutics. 1997;282 (3):1632-42.

Bromberg KD, Ma'ayan A, Neves SR, Iyengar R. Design logic of a cannabinoid receptor signaling network that triggers neurite outgrowth. Science. 2008;320 (5878):903-9.

Bronander KA, Bloch MJ. Potential role of the endocannabinoid receptor antagonist rimonabant in the management of cardiometabolic risk: a narrative review of available data. Vascular health and risk management. 2007;3 (2):181-90.

Brownell KD, Yach D. Lessons from a small country about the global obesity crisis. Globalization and health. 2006;2:11.

Brunzell JD, Fujimotor WY. Body fat distribution and dyslipidemia. Am J Med. 1995;99 (5):457-8.

Bruun JM, Lihn AS, Verdich C, et al. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab. 2003;285 (3):E527-33.

Bruun, J. M.Lihn, A. S.Verdich, C.Pedersen, S. B.Toubro, S.Astrup, A.Richelsen, B.. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab. 2003;285:E527-33.

Buckley NE. The peripheral cannabinoid receptor knockout mice: an update. British Journal of Pharmacology. 2008;153 (2):309-18.

Buckley NE. The peripheral cannabinoid receptor knockout mice: an update. British Journal of Pharmacology. 2007;27 (14):3695-702.

Budney AJ, Kandel DB, Cherek DR, Martin BR, Stephens RS, Roffman R. College on problems of drug dependence meeting, Puerto Rico (June 1996) marijuana use and dependence. Drug Alcohol Depend. 1997;45:1-11.

Burdyga G, Lal S, Varro A, Dimaline R, Thompson DG, Dockray GJ. Expression of cannabinoid CB1 receptors by vagal afferent neurons is inhibited by cholecystokinin. J Neurosci. 2004;24 (11):2708-15.

Burdyga, G.Lal, S.Varro, A.Dimaline, R.Thompson, D. G.Dockray, G. J.. Expression of cannabinoid CB1 receptors by vagal afferent neurons is inhibited by cholecystokinin. J Neurosci. 2004;24:2708-15.

Burstein S. PPAR-gamma: a nuclear receptor with affinity for cannabinoids. Life Sci. 2005;77 (14):1674-84.

Burstein S, Menezes F, Williamson E, Mechoulam R. Metabolism of delta 1(6)-tetrahydro--cannabinol, an active marihuana constituent. Nature. 1970;225 (5227):87-8.

Butler AA. The melanocortin system and energy balance. Peptides. 2006;27 (2):281-90.

Butler, A. A.. The melanocortin system and energy balance. Peptides. 2006;27:281-90.

Cabral G, Marciano-Cabral F. Cannabinoid receptors in microglia of the central nervous system: immune functional relevance. Journal of leukocyte biology. 2005;78 (6):1192-7.

Cabral G, Raborn ES, Griffin L, Dennis J, Marciano-Cabral F. CB(2) receptors in the brain: role in central immune function. British Journal of Pharmacology. 2008;153 (2):240-51.

Caille S, Alvarez-Jaimes L, Polis I, Stouffer GA, Parsons LH. Specific alterations of extracellular endocannabinoid levels in the nucleus accumbens by ethanol, heroin, and cocaine self-administration. J Neurosci. 2007;27 (14):3695-702.

Caille S, Parsons LH. Cannabinoid modulation of opiate reinforcement through the ventral striatopallidal pathway. Neuropsychopharmacology. 2006;31 (4):804-13.

Caille S, Parsons LH. SR141716A reduces the reinforcing properties of heroin but not heroin-induced increases in nucleus accumbens dopamine in rats. European Journal of Neuroscience. 2003;18 (11):3145-9.

Cani PD, Montoya ML, Neyrinck AM, Delzenne NM, Lambert DM. Potential modulation of plasma ghrelin and glucagon-like peptide-1 by anorexigenic cannabinoid compounds, SR141716A (rimonabant) and oleoylethanolamide. The British journal of nutrition. 2004;92 (5):757-61.

Cani, P. D.Montoya, M. L.Neyrinck, A. M.Delzenne, N. M.Lambert, D. M.. Potential modulation of plasma ghrelin and glucagon-like peptide-1 by anorexigenic cannabinoid compounds, SR141716A (rimonabant) and oleoylethanolamide. Br J Nutr. 2004;92:757-61.

Cannich A, Wotjak CT, Kamprath K, Hermann H, Lutz B, Marsicano G. CB1 cannabinoid receptors modulate kinase and phosphatase activity during extinction of conditioned fear in mice. Learning & memory (Cold Spring Harbor, N.Y. 2004;11 (5):625-32.

Caraceni P, Domenicali M, Bernardi M. The endocannabinoid system and liver diseases. Journal of neuroendocrinology. 2008;20 Suppl 1:47-52.

Carai MA, Colombo G, Gessa GL. Rimonabant: the first therapeutically relevant cannabinoid antagonist. Life Sci. 2005;77 (19):2339-50.

Carlisle SJ, Marciano-Cabral F, Staab A, Ludwick C, Cabral G. Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. International immunopharmacology. 2002;2 (1):69-82.

Carlson G, Wang Y, Alger BE. Endocannabinoids facilitate the induction of LTP in the hippocampus. Nature Neuroscience. 2002;5 (8):723-4.

Carney JM, Balster RL, Martin BR, Harris LS. Effects of systemic and intraventricular administration of cannabinoids on schedule-controlled responding in the squirrel monkey. J Pharmacol Exp Ther. 1979;210:399-404.

Carr MC, Brunzell JD. Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. The Journal of clinical endocrinology and metabolism. 2004;89 (6):2601-7.

Carriba P, Ortiz O, Patkar K, et al. Striatal adenosine A2A and cannabinoid CB1 receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids. Neuropsychopharmacology. 2007;32 (11):2249-59.

Carta G, Gessa GL, Nava F. Dopamine D(2) receptor antagonists prevent delta(9)-tetrahydrocannabinol-induced antinociception in rats. Eur J Pharmacol. 1999;384 (2-3):153-6.

Castane A, Valjent E, Ledent C, Parmentier M, Maldonado R, Valverde O. Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence. Neuropharmacology. 2002;43 (5):857-67.

Cavuoto P, McAinch AJ, Hatzinikolas G, Janovska A, Game P, Wittert GA. The expression of receptors for endocannabinoids in human and rodent skeletal muscle. Biochemical and Biophysical Research Communications. 2007;364 (1):105-10.

Centonze D, Finazzi-Agro A, Bernardi G, Maccarrone M. The endocannabinoid system in targeting inflammatory neurodegenerative diseases. Trends Pharmacol Sci. 2007;28 (4):180-7.

Centonze D, Rossi S, De CV, et al. Chronic cocaine sensitizes striatal GABAergic synapses to the stimulation of cannabinoid CB1 receptors. European Journal of Neuroscience. 2007;25 (6):1631-40.

Centonze D, Rossi S, Finazzi-Agro A, Bernardi G, Maccarrone M. The (endo)cannabinoid system in multiple sclerosis and amyotrophic lateral sclerosis. International review of neurobiology. 2007;82:171-86.

Chakrabarti B, Kent L, Suckling J, Bullmore E, Baron-Cohen S. Variations in the human cannabinoid receptor (CNR1) gene modulate striatal responses to happy faces. European Journal of Neuroscience. 2006;23 (7):1944-8.

Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: more than just another fat cell hormone?. Diabetes Care. 2003;26 (8):2442-50.

Charalambous A, Lin S, Marciniak G, Banijamali A, Friend FL, Compton DR, Martin BR, Makriyannis A. Pharmacological evaluation of halogenated delta 8-THC analogs. Pharmacol Biochem Behav. 1991;40:509-12.

Charalambous A, Yan G, Houston DB, Howlett AC, Compton DR, Martin BR, Makriyannis A. 5'-Azido-delta 8-THC: a novel photoaffinity label for the cannabinoid receptor. J Med Chem. 1992;35:3076-9.

Chaytor AT, Martin PE, Evans WH, Randall MD, Griffith TM. The endothelial component of cannabinoid-induced relaxation in rabbit mesenteric artery depends on gap junctional communication. Journal of Physiology. 1999;520 Pt 2:539-50.

Cheer JF, Wassum KM, Heien ML, Phillips PE, Wightman RM. Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats. J Neurosci. 2004;24 (18):4393-400.

Cheer JF, Wassum KM, Sombers LA, et al. Phasic dopamine release evoked by abused substances requires cannabinoid receptor activation. J Neurosci. 2007;27 (4):791-5.

Chemin J, Monteil A, Perez-Reyes E, Nargeot J, Lory P. Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide. The EMBO journal. 2001;20 (24):7033-40.

Chemin, J.Monteil, A.Perez-Reyes, E.Nargeot, J.Lory, P.. Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide. Embo J. 2001;20:7033-40.

Chen JP, Paredes W, Li J, Smith D, Lowinson J, Gardner EL. Delta 9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis. Psychopharmacology. 1990;102 (2):156-62.

Chen K, Neu A, Howard AL, et al. Prevention of plasticity of endocannabinoid signaling inhibits persistent limbic hyperexcitability caused by developmental seizures. J Neurosci. 2007;27 (1):46-58.

Chen RZ, Frassetto A, Lao JZ, et al. Pharmacological evaluation of LH-21, a newly discovered molecule that binds to cannabinoid CB1 receptor. Eur J Pharmacol. 2008;584 (2-3):338-42.

Chhatwal JP, Stanek-Rattiner L, Davis M, Ressler KJ. Amygdala BDNF signaling is required for consolidation but not encoding of extinction. Nature Neuroscience. 2006;9 (7):870-2.

Chiang K, Gerber AL, Sipe JC, Cravatt BF. Reduced cellular expression and activity of the P129T mutant of human fatty acid amide hydrolase: evidence for a link between defects in the endocannabinoid system and problem drug use. Human molecular genetics. 2004;13 (18):2113-9.

Chin CL, Tovcimak AE, Hradil VP, et al. Differential effects of cannabinoid receptor agonists on regional brain activity using pharmacological MRI. British Journal of Pharmacology. 2008;153 (2):367-79.

Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup J. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet. 2007;370 (9600):1706-13.

Chung WK, Leibel RL. Molecular physiology of syndromic obesities in humans. Trends in endocrinology and metabolism: TEM. 2005;16 (6):267-72.

Cippitelli A, Bilbao A, Gorriti MA, et al. The anandamide transport inhibitor AM404 reduces ethanol self-administration. European Journal of Neuroscience. 2007;26 (2):476-86.

Cippitelli A, Bilbao A, Hansson AC, et al. Cannabinoid CB1 receptor antagonism reduces conditioned reinstatement of ethanol-seeking behavior in rats. European Journal of Neuroscience. 2005;21 (8):2243-51.

Cleland SJ, Sattar N. Does rimonabant pull its weight for type 2 diabetes?. Lancet. 2006;368 (9548):1632-4.

Clement AB, Hawkins EG, Lichtman AH, Cravatt BF. Increased seizure susceptibility and proconvulsant activity of anandamide in mice lacking fatty acid amide hydrolase. J Neurosci. 2003;23 (9):3916-23.

Cnop M, Havel P, Utzschneider KM, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia. 2003;46 (4):459-69.

Cnop, M.Havel, P. J.Utzschneider, K. M.Carr, D. B.Sinha, M. K.Boyko, E. J.Retzlaff, B. M.Knopp, R. H.Brunzell, J. D.Kahn, S. E.. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia. 2003;46:459-69.

Cohen C, Perrault G, Griebel G, Soubrie P. Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716). Neuropsychopharmacology. 2005;30 (1):145-55.

Cohen C, Perrault G, Voltz C, Steinberg R, Soubrie P. SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behavioural pharmacology. 2002;13 (5-6):451-63.

Colombo G, Agabio R, Diaz G, Lobina C, Reali R, Gessa GL. Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci. 1998;63 (8):PL113-7.

Colombo G, Agabio R, Fa M, et al. Reduction of voluntary ethanol intake in ethanol-preferring sP rats by the cannabinoid antagonist SR-141716. Alcohol and alcoholism (Oxford, Oxfordshire). 1998;33 (2):126-30.

Colombo G, Serra S, Brunetti G, et al. Stimulation of voluntary ethanol intake by cannabinoid receptor agonists in ethanol-preferring sP rats. Psychopharmacology. 2002;159 (2):181-7.

Combs TP, Berg AH, Obici S, Scherer PE, Rossetti L. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest. 2001;108 (12):1875-81.

Combs, T. P.Berg, A. H.Obici, S.Scherer, P. E.Rossetti, L.. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest. 2001;108:1875-81.

Compton DR, Aceto MD, Lowe J, Martin BR. In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J Pharmacol Exp Ther. 1996;277:586-94.

Compton DR, Aceto MD, Lowe J, Martin BR. In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity. The Journal of Pharmacology and Experimental Therapeutics. 1996;277 (2):586-94.

Compton DR, Dewey WL, Martin BR. Cannabis dependence and tolerance production. Adv Alcohol Subst Abuse. 1990;9:129-47.

Compton DR, Gold LH, Ward SJ, Balster RL, Martin BR. Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from delta 9-tetrahydrocannabinol. J Pharmacol Exp Ther. 1992;263:1118-26.

Compton DR, Johnson MR, Melvin LS, Martin BR. Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents. J Pharmacol Exp Ther. 1992;260:201-9.

Compton DR, Little PJ, Martin BR, Gilman JW, Saha JK, Jorapur VS, Sard HP, Razdan RK. Synthesis and pharmacological evaluation of amino, azido, and nitrogen mustard analogues of 10-substituted cannabidiol and 11- or 12-substituted delta 8-tetrahydrocannabinol. J Med Chem. 1990;33:1437-43.

Compton DR, Martin BR. The effect of the enzyme inhibitor phenylmethylsulfonyl fluoride on the pharmacological effect of anandamide in the mouse model of cannabimimetic activity. J Pharmacol Exp Ther. 1997;283:1138-43.

Compton DR, Martin BR. Pharmacological evaluation of water soluble cannabinoids and related analogs. Life Sci. 1990;46:1575-85.

Compton DR, Prescott WR Jr, Martin BR, Siegel C, Gordon PM, Razdan RK. Synthesis and pharmacological evaluation of ether and related analogues of delta 8-, delta 9-, and delta 9,11-tetrahydrocannabinol. J Med Chem. 1991;34:3310-6.

Compton DR, Prescott WR, Siegel CS, Gordon PM, Razdan RK, Martin BR. Evaluation of ether and free hydroxyl analogs of delta-8, delta-9, 11-THC as cannabinoid antagonists. NIDA Res Monogr. 1990;105:297-8.

Compton DR, Rice KC, De Costa BR, Razdan RK, Melvin LS, Johnson MR, Martin BR. Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J Pharmacol Exp Ther. 1993;265:218-26.

Cook SA, Lowe JA, Martin BR. CB1 receptor antagonist precipitates withdrawal in mice exposed to Delta9-tetrahydrocannabinol. J Pharmacol Exp Ther. 1998;285:1150-6.

Cook SA, Welch SP, Lichtman AH, Martin BR. Evaluation of cAMP involvement in cannabinoid-induced antinociception. Life Sci. 1995;56:2049-56.

Cooper SJ. Endocannabinoids and food consumption: comparisons with benzodiazepine and opioid palatability-dependent appetite. Eur J Pharmacol. 2004;500 (1-3):37-49.

Corbille AG, Valjent E, Marsicano G, et al. Role of cannabinoid type 1 receptors in locomotor activity and striatal signaling in response to psychostimulants. J Neurosci. 2007;27 (26):6937-47.

Correa F, Mestre L, Molina-Holgado E, et al. The role of cannabinoid system on immune modulation: therapeutic implications on CNS inflammation. Mini reviews in medicinal chemistry. 2005;5 (7):671-5.

Correa, F.Mestre, L.Molina-Holgado, E.Arevalo-Martin, A.Docagne, F.Romero, E.Molina-Holgado, F.Borrell, J.Guaza, C.. The role of cannabinoid system on immune modulation: therapeutic implications on CNS inflammation. Mini Rev Med Chem. 2005;5:671-5.

Cossu G, Ledent C, Fattore L, et al. Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse. Behavioural brain research. 2001;118 (1):61-5.

Costa B, Siniscalco D, Trovato AE, et al. AM404, an inhibitor of anandamide uptake, prevents pain behaviour and modulates cytokine and apoptotic pathways in a rat model of neuropathic pain. British Journal of Pharmacology. 2006;148 (7):1022-32.

Costa B, Trovato AE, Colleoni M, Giagnoni G, Zarini E, Croci T. Effect of the cannabinoid CB1 receptor antagonist, SR141716, on nociceptive response and nerve demyelination in rodents with chronic constriction injury of the sciatic nerve. Pain. 2005;116 (1-2):52-61.

Cota D. Role of the endocannabinoid system in energy balance regulation and obesity. Frontiers of hormone research. 2008;36:135-45.

Cota D. CB1 receptors: emerging evidence for central and peripheral mechanisms that regulate energy balance, metabolism, and cardiovascular health. Diabetes/metabolism research and reviews. 2007;23 (7):507-17.

Cota D, Marsicano G, Lutz B, et al. Endogenous cannabinoid system as a modulator of food intake. International Journal of Obesity and Related Metabolic Disorders. 2003;27 (3):289-301.

Cota D, Marsicano G, Tschop MH, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest. 2003;112 (3):423-31.

Cota D, Proulx K, Smith KA, et al. Hypothalamic mTOR signaling regulates food intake. Science. 2006;312 (5775):927-30.

Cota D, Steiner MA, Marsicano G, et al. Requirement of cannabinoid receptor type 1 for the basal modulation of hypothalamic-pituitary-adrenal axis function. Endocrinology. 2006;148 (4):1574-81.

Cota D, Tschop MH, Horvath TL, Levine AS. Cannabinoids, opioids and eating behavior: the molecular face of hedonism?. Brain research reviews. 2006;51 (1):85-107.

Cota, D.Marsicano, G.Tschop, M.Grubler, Y.Flachskamm, C.Schubert, M.Auer, D.Yassouridis, A.Thone-Reineke, C.Ortmann, S.Tomassoni, F.Cervino, C.Nisoli, E.Linthorst, A. C.Pasquali, R.Lutz, B.Stalla, G. K.Pagotto, U.. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest. 2003;112:423-31.

Cota, D.Tschop, M. H.Horvath, T. L.Levine, A. S.. Cannabinoids, opioids and eating behavior: the molecular face of hedonism?. Brain Res Brain Res Rev. 2006;51:85-107.

Cota, DWoods, SC. The role of the endocannabinoid system in the regulation of energy homeostasis. Curr Opin Endocrinol Diabetes. 2005;12:338-351.

Cote M, Matias I, Lemieux I, et al. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. International journal of obesity. 2007;31 (4):692-9.

Cote M, Mauriege P, Bergeron J, et al. Adiponectinemia in visceral obesity: impact on glucose tolerance and plasma lipoprotein and lipid levels in men. The Journal of clinical endocrinology and metabolism. 2005;90 (3):1434-9.

Cote, M.Mauriege, P.Bergeron, J.Almeras, N.Tremblay, A.Lemieux, I.Despres, J. P.. Adiponectinemia in visceral obesity: impact on glucose tolerance and plasma lipoprotein and lipid levels in men. J Clin Endocrinol Metab. 2005;90:1434-9.

Cox ML, Haller VL, Welch SP. Synergy between delta9-tetrahydrocannabinol and morphine in the arthritic rat. Eur J Pharmacol. 2007;567 (1-2):125-30.

Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, Lichtman AH. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci U S A. 2001;98:9371-6.

Cravatt BF, Demarest K, Patricelli MP, et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl. Acad. Sci. USA. 2001;98 (16):9371-6.

Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature. 1996;384 (6604):83-7.

Cravatt BF, Lichtman AH. Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system. Current opinion in chemical biology. 2003;7 (4):469-75.

Cravatt, B. F.Demarest, K.Patricelli, M. P.Bracey, M. H.Giang, D. K.Martin, B. R.Lichtman, A. H.. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci U S A. 2001;98:9371-6.

Cravatt, B. F.Giang, D. K.Mayfield, S. P.Boger, D. L.Lerner, R. A.Gilula, N. B.. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature. 1996;384:83-7.

Cristino L, De PL, Pryce G, Baker D, Guglielmotti V, Di Marzo V. Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience. 2006;139 (4):1405-15.

Croci T, Landi M, Galzin AM, Marini P. Role of cannabinoid CB1 receptors and tumor necrosis factor-alpha in the gut and systemic anti-inflammatory activity of SR 141716 (rimonabant) in rodents. British Journal of Pharmacology. 2003;140 (1):115-22.

Crocker PJ, Mahadevan A, Wiley JL, Martin BR, Razdan RK. The role of fluorine substitution in the structure-activity relationships (SAR) of classical cannabinoids. Bioorg Med Chem Lett. 2007;17:1504-7.

Cross-Mellor SK, Ossenkopp KP, Piomelli D, Parker LA. Effects of the FAAH inhibitor, URB597, and anandamide on lithium-induced taste reactivity responses: a measure of nausea in the rat. Psychopharmacology. 2007;190 (2):135-43.

Croxford JL. Therapeutic potential of cannabinoids in CNS disease. CNS drugs. 2003;17 (3):179-202.

Croxford JL, Pryce G, Jackson SJ, et al. Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis. Cannabinoid mediated neuroprotection. 2007;21 (10):2431-41.

Cudaback E, Stella N. Targeting astrocytomas and invading immune cells with cannabinoids: a promising therapeutic avenue. Molecular neurobiology. 2007;36 (1):36-44.

Cunningham LA, Wetzel M, Rosenberg GA. Multiple roles for MMPs and TIMPs in cerebral ischemia. Glia. 2005;50 (4):329-39.

Cvetkovic, V.Brischoux, F.Griffond, B.Bernard, G.Jacquemard, C.Fellmann, D.Risold, P. Y.. Evidence of melanin-concentrating hormone-containing neurons supplying both cortical and neuroendocrine projections. Neuroscience. 2003;116:31-5.

Daigle TL, Kearn CS, Mackie K. Rapid CB(1) cannabinoid receptor desensitization defines the time course of ERK1/2 MAP kinase signaling. Neuropharmacology. 2008;54 (1):36-44.

Dainese E, Oddi S, Bari M, Maccarrone M. Modulation of the endocannabinoid system by lipid rafts. Curr Med Chem. 2007;14 (25):2702-15.

Dallman MF. Fast glucocorticoid feedback favors 'the munchies'. Trends in endocrinology and metabolism: TEM. 2003;14 (9):394-6.

Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation. 2005;111 (11):1448-54.

Daniel H, Crepel F. Control of Ca(2+) influx by cannabinoid and metabotropic glutamate receptors in rat cerebellar cortex requires K(+) channels. Journal of Physiology. 2001;537 (Pt 3):793-800.

D'Argenio G, Petrosino S, Gianfrani C, et al. Overactivity of the intestinal endocannabinoid system in celiac disease and in methotrexate-treated rats. Journal of molecular medicine (Berlin, Germany). 2007;85 (5):523-30.

<a id=